CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia.

S. J. Cano, J. C. Hobart, M. Edwards, R. Fitzpatrick, K. Bhatia, A. J. Thompson, T. T. Warner*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

We compared the responsiveness of the Cervical Dystonia Impact Profile (CDIP-58), Medical Outcome Study Short Form-Health Survey (SF-36), Functional Disability Questionnaire (FDQ), and Pain and Activities of Daily Living subscales of the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) in participants with cervical dystonia treated with botulinum toxin A. Subscales of CDIP-58 were more sensitive in detecting statistical and clinical change than comparable subscales of the SF-36, FDQ, and TWSTRS.
Original languageEnglish
Pages (from-to)2230-2232
Number of pages0
JournalNeurology
Volume67
Issue number12
DOIs
Publication statusPublished - 26 Dec 2006

Keywords

  • Adult
  • Aged
  • Botulinum Toxins
  • Type A
  • England
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neck Pain
  • Outcome Assessment
  • Health Care
  • Prevalence
  • Prognosis
  • Psychometrics
  • Quality of Life
  • Reproducibility of Results
  • Risk Assessment
  • Risk Factors
  • Sensitivity and Specificity
  • Sickness Impact Profile
  • Torticollis
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia.'. Together they form a unique fingerprint.

Cite this